



RESEARCH NOTE

REVISED Predicted protein interactions of IFITMs may shed light on mechanisms of Zika virus-induced microcephaly and host invasion [version 2; referees: 2 approved, 1 approved with reservations, 1 not approved]

Previously titled: Predicted protein interactions of IFITMs which inhibit Zika virus infection

Madhavi K. Ganapathiraju^{1,2}, Kalyani B. Karunakaran³, Josefina Correa-Menéndez²

¹Intelligent Systems Program, University of Pittsburgh, Pittsburgh, PA, USA

²Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA

³Supercomputer Education and Research Centre, Indian Institute of Science, Bangalore, India

v2 First published: 05 Aug 2016, 5:1919 (doi: [10.12688/f1000research.9364.1](https://doi.org/10.12688/f1000research.9364.1))
 Latest published: 21 Nov 2017, 5:1919 (doi: [10.12688/f1000research.9364.2](https://doi.org/10.12688/f1000research.9364.2))

Abstract

After the first reported case of Zika virus (ZIKV) in Brazil, in 2015, a significant increase in the reported cases of microcephaly was observed. Microcephaly is a neurological condition in which the infant’s head is significantly smaller with complications in brain development. Recently, two small membrane-associated interferon-inducible transmembrane proteins (IFITM1 and IFITM3) have been shown to repress members of the flaviviridae family which includes ZIKV. However, the exact mechanisms leading to the inhibition of the virus are yet unknown. Here, we assembled an interactome of IFITM1 and IFITM3 with known protein-protein interactions (PPIs) collected from publicly available databases and novel PPIs predicted using the High-confidence Protein-Protein Interaction Prediction (HiPPIP) model. We analyzed the functional and pathway associations of the interacting proteins, and found that there are several immunity pathways (toll-like receptor signaling, cd28 signaling in T-helper cells, crosstalk between dendritic cells and natural killer cells), neuronal pathways (axonal guidance signaling, neural tube closure and actin cytoskeleton signaling) and developmental pathways (neural tube closure, embryonic skeletal system development) that are associated with these interactors. Our novel PPIs associate cilia dysfunction in ependymal cells to microcephaly, and may also shed light on potential targets of ZIKV for host invasion by immunosuppression and cytoskeletal rearrangements. These results could help direct future research in elucidating the mechanisms underlying host defense to ZIKV and other flaviviruses.



This article is included in the [Zika & Arbovirus Outbreaks](#) collection.

Open Peer Review

Referee Status: ✓ ? ✗ ✓

	Invited Referees			
	1	2	3	4
REVISED	✓	?		✓
version 2	report	report		report
published				
21 Nov 2017	↑	↑		
version 1	✓	?	✗	
published	report	report	report	
05 Aug 2016				

- Judith Klein-Seetharaman**, University of Warwick, UK
- Nicholas Eyre**, University of Adelaide, Australia
- Sandeep Chakraborty**, University of California, USA
- Rama Rao Damerla** , Memorial Sloan Kettering Cancer Center, USA

Discuss this article

Comments (0)

Corresponding author: Madhavi K. Ganapathiraju (madhavi@pitt.edu)

Author roles: **Ganapathiraju MK:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Karunakaran KB:** Investigation, Writing – Original Draft Preparation; **Correa-Menéndez J:** Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

How to cite this article: Ganapathiraju MK, Karunakaran KB and Correa-Menéndez J. **Predicted protein interactions of IFITMs may shed light on mechanisms of Zika virus-induced microcephaly and host invasion [version 2; referees: 2 approved, 1 approved with reservations, 1 not approved]** *F1000Research* 2017, **5**:1919 (doi: [10.12688/f1000research.9364.2](https://doi.org/10.12688/f1000research.9364.2))

Copyright: © 2017 Ganapathiraju MK *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: MKG's work is funded by Biobehavioral Research Awards for Innovative New Scientists (BRAINS) grant (R01MH094564) from National Institute of Mental Health of National Institutes of Health of USA.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

First published: 05 Aug 2016, **5**:1919 (doi: [10.12688/f1000research.9364.1](https://doi.org/10.12688/f1000research.9364.1))

REVISED Amendments from Version 1

In this revision, we have added additional details to the Introduction and Methods sections, and added a substantial Discussion section that presents 3 hypotheses about mechanisms of Zika-virus induced microcephaly and host-invasion by the virus, based on the functional significance of predicted interactors of IFITMs. We have added 2 new authors, Kalyani B. Karunakaran and Josefina Correa-Menéndez who contributed to this revision.

We have added a brief description about HiPPIP, the computational method that was employed to predict protein-protein interactions. This method has been described in detail in our prior publication (*npj Schizophrenia* 2, Article number: 16012, 2016, doi:10.1038/npjSchz.2016.12).

See referee reports

Introduction

Zika virus (ZIKV) is a flavivirus that was initially isolated from rhesus monkeys in 1947 and was first reported in humans in 1952¹. The flavivirus genus contains around 70 viruses belonging to the family *Flaviviridae*, a family of positive sense, single-stranded, enveloped RNA viruses², that also include Dengue virus, West Nile virus (WNV), tick-borne encephalitis virus, Japanese encephalitis virus, yellow fever virus, and Hepatitis C virus³. Until recently, ZIKV reports had been limited to Africa and Asia⁴ but it became a wide-spread ZIKV epidemic⁵. The virus spread rapidly across the Americas and was declared a ‘global emergency’ by the World Health Organization⁶. It is mostly transmitted by mosquitoes and clinical manifestations include rash, mild fever, arthralgia, conjunctivitis, myalgia, and headaches. In addition, the virus can be transmitted sexually, with the risk of infection persisting for several months after initial contact⁷. While the symptoms of ZIKV can be mild¹, the virus has been linked to two more serious afflictions: Guillen-Barré syndrome (GBS)^{8,9} and microcephaly^{10–14}, both of which are serious neurological conditions. Microcephaly results in reduced head circumference measurement in infants, exhibiting complications in brain development. Of particular concern is the attribution of microcephaly to infection with ZIKV occurring between the first two trimesters of pregnancy^{13,14}. Evidence linking ZIKV to microcephaly includes detection of ZIKV RNA in tissue such as the placenta and amniotic fluid of pregnant women with ZIKV, as well as in the brains of stillborn infants with microcephaly¹⁵. In a study with human induced pluripotency stem cells, the mechanism of ZIKV related cell death has been elucidated. This study demonstrated that ZIKV infects human embryonic cortical neural progenitor cells (hNPCs), ultimately leading to attenuated population growth mediated by virally induced caspase-3-mediated apoptosis and cell-cycle dysregulation¹⁶. Furthermore, mice studies showed that ZIKV infection can lead to nerve degeneration, softening of the brain and porencephaly¹⁷. Additional studies have assessed the causal relation between ZIKV infection and birth defects, and the role of ZIKV as a cause of congenital defects and as a trigger of GBS has been established^{10,18,19}.

Recently, it was discovered that two small membrane-associated interferon inducible transmembrane proteins (IFITMs) IFITM1 and IFITM3 play a protective role against ZIKV infection by inhibiting replication of the virus and preventing cell death⁷. The IFITM protein family belongs to a group of small (10 – 15kDa)²⁰ interferon stimulated genes (ISGs), which are in turn produced by the interferon system²¹. The interferon system is the host’s primary response against infection which restricts entry and fusion from late endosomes²², with some ISGs being involved in suppressing the early stages of viral replication^{21,23,24}. IFITMs are located at the cell plasma and endosomal membranes, which are the means of entry of many viruses²⁵. This protein family protects the host against viral infection by directly restricting entry and fusion from late endosomes²⁶.

Flaviviruses depend on the intracellular membrane of their host throughout their lifecycle^{27–29}. Mice that are lacking immune sensors, signaling pathways and effector molecules were found to be susceptible to flavivirus infection highlighting the importance of the host’s innate immune response to these viruses^{5,30,31}. Recent literature has demonstrated that during ZIKV infection, the production of several types of interferon and ISGs is increased, and that IFITM1 and IFITM3 are involved in inhibiting ZIKV infection during the early stages of pathogenesis^{7,30–33}. Enveloped viruses, such as ZIKV, have a membrane of host cell lipids that contains viral fusion proteins; these proteins mediate fusion between the virus and the endosomal membrane of the host cell, a necessary step for initiating infection^{21,34}. The precise mechanisms by which IFITMs inhibit infection are yet to be described. However, IFITM3 has been shown to impact the function of vesicle-associated membrane protein (VAMP)-associated protein A (VAPA) and oxysterol-binding protein (OSBP) by directly interacting with VAPA. This leads to the accumulation of cholesterol in multivesicular bodies and late endosomes, preventing the fusion of the intraluminal virion-containing vesicles with endosomal membranes³⁵. Additionally, IFITM1 has been shown to suppress cell to cell fusion (syncytia formation) by localizing to the plasma membrane after interferon induction²¹.

There are additional reasons to explore the role of IFITMs in ZIKV restriction. For instance, murine models of ZIKV infection require deficiency of type 1 interferon signaling, which suggests a role for ISGs in restricting infection^{7,36}. Therefore, prior to the induction of ISGs, IFITMs may provide initial defense against the infection⁷. Furthermore, IFITMs have been found to restrict virus replication among other flaviviruses, including West Nile virus and Dengue virus^{23,37,38}. Recently, the role of IFITM3 as an antiviral protein against West Nile virus has been explored *in vivo*, and *Ifitm3*^{-/-} mice exhibited a greater susceptibility to lethal viral infection, with a greater accumulation of viral protein in peripheral organs and central nervous system tissues²⁶. Additionally, IFITM1, IFITM2, and IFITM3 have been shown to have antiviral properties in humans. Polymorphisms in human IFITM3 correlate with the severity of influenza A infection³⁸. These functional members are expressed across a variety of tissues in humans and out of the

three, IFITM3 is thought to be the most potent line of defense against viral infection²¹.

As the mechanism through which IFITM1 and IFITM3 mediate restriction is unknown, computational methods could accelerate research by presenting testable hypotheses. Protein-protein interactions (PPIs) prove to be valuable in understanding the function of a protein, and specifically in how it plays a role in causing or preventing disease. Motivated by this, we had developed a computational model called ‘High-confidence Protein-Protein Interaction Prediction’ (HiPPIP) model that identifies novel PPIs in the human interactome³⁹ using machine learning to classify features of protein-pairs such as colocalization, coexpression, shared molecular function and biological processes. *HiPPIP* was also instrumental in discovering that *oligoadenylate synthetase like* protein (OASL) interacts with *retinoic acid inducible gene 1* product (RIG-I) to activate the RIG-I immunity pathway during influenza viral infection inhibiting virus replication⁴⁰. Functional studies initiated solely by this predicted PPI showed that human OASL binds to dsRNA to enhance RIG-I signaling, and that boosting OASL can help inhibit viral infection⁴⁰. Using novel PPIs predicted with HiPPIP, we could explain the apparent discordance between modern and historical genetic basis of schizophrenia⁴¹, and the role of cilia in the pathogenesis of congenital heart disease⁴². PPIs predicted by our method revealed a molecular basis for the negative association between schizophrenia and rheumatoid arthritis⁴³. These successes demonstrate that there is enormous potential for biomedical discovery buried in the largely-unexplored novel PPIs in the human interactome.

In this work, we applied the HiPPIP model to discover novel PPIs of IFITM1 and IFITM3, to potentially accelerate the discovery of the mechanism by which they inhibit ZIKV and other viral infections.

Methods

We assembled the PPIs of IFITM1 and IFITM3 (‘IFITM interactome’) by predicting novel PPIs with HiPPIP³⁹ and collecting known PPIs from the Human Protein Reference Database (HPRD)⁴⁴ and Biological General Repository for Interaction Datasets (BioGRID)⁴⁵. HiPPIP uses a score cut-off of 0.5 to achieve a high precision of 97.5%, albeit successfully predicting only a few PPIs (recall of 5%), when evaluated on a held-out test data. Thus, the novel PPIs predicted by HiPPIP are highly dependable to lead to successful experiments. Furthermore, predicted PPIs with scores ranging from 0.41 to 0.65 were experimentally validated and found to be true interacting pairs³⁹. The HiPPIP model was also computationally evaluated on hub proteins and showed a better performance when compared to Qi *et al.*'s model^{39,46}. HiPPIP is configured to present protein-pairs achieving a score of greater than 0.5 to be novel PPIs. Additional information regarding experimental validation of predicted interactions and model evaluation are available in prior work³⁹.

IFITM interactome figure was created using Cytoscape⁴⁷. Pathways associated with proteins in the interactome were collected using Ingenuity Pathway Analysis® suite (www.ingenuity.com).

Gene Ontology (GO) terms enriched in the interactome were computed using the BiNGO plugin of Cytoscape⁴⁸.

Results

We assembled the PPIs of IFITM1 and IFITM3 (‘IFITM interactome’, Figure 1) by computing novel PPIs using the HiPPIP model and collecting known PPIs from publicly available databases. We found that the interactors of IFITMs are involved in relevant functions including immunity. Functional annotations of the novel interactors of IFITM1 and IFITM3, sourced from Wiki-Pi⁴⁹, revealed two main categories: development and innate immunity.

Pathways associated with IFITM interactome computed with Ingenuity Pathway Analysis Suite® are given in Table 1. Gene Ontology biological process terms associated with the interactome, compiled with BiNGO⁴⁸ are shown in Figure 2 and Table 2.

DEAF1, which encodes for deformed epidermal autoregulatory factor 1 homolog, is a transcription factor that binds to TTCG elements in DNA and is involved in neural tube closure, embryonic skeletal development and anatomic structure morphogenesis, and other functions⁵⁰. Additionally, DEAF1 is preferentially expressed in the CNS, particularly during early embryonic development. Mutations in DEAF1 have been associated with intellectual disability⁵¹. A study involving Sendai-virus infected mouse embryonic fibroblasts (MEFs) found that DEAF1-/- deficient mice had lower levels of IFN-beta mRNA compared to the wild type controls, along with lower mRNA levels of other markers of viral infection⁵².

FNDC3B, a membrane protein, was found to be associated with heart rate, height and corneal structure through genome-wide association studies. While its own functions are unknown, its known interactors are involved in regulation of glial cell apoptotic process, regulation of ion transport (sodium, potassium, calcium) and several cardiac processes.




Figure 1. Protein-protein interactions (PPIs) of IFITM1 and IFITM3: Known PPIs were assembled from HPRD and BioGRID databases and novel PPIs were predicted using HiPPIP model.

Novel interactors of IFITM1 and IFITM3 are shown as red colored nodes while previously known interactors are shown as light blue colored nodes. Novel interactors of IFITM1 and IFITM3 are shown as red colored nodes while previously known interactors are shown as light blue colored nodes. The known interactions are curated by (HPRD)⁴⁴ and Biological General Repository for Interaction Datasets (BioGRID)⁴⁵; any interactions that may be published in literature but not curated into these databases would not be seen here.

Table 1. Pathways associated with IFITMs and their interactor. Pathway associations were computed with Ingenuity Pathway Analysis Suite®. Novel interactors are shown in bold.

Gene	Associated pathways
AGTR2	Gαi Signaling Renin-Angiotensin Signaling
ARPC1B	Axonal Guidance Signaling Signaling by Rho Family GTPases Actin Cytoskeleton Signaling Integrin Signaling Clathrin-mediated Endocytosis Signaling Ephrin Receptor Signaling RhoGDI Signaling Cdc42 Signaling Epithelial Adherens Junction Signaling RhoA Signaling CD28 Signaling in T Helper Cells fMLP Signaling in Neutrophils Rac Signaling Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes Regulation of Actin-based Motility by Rho Remodeling of Epithelial Adherens Junctions Actin Nucleation by ARP-WASP Complex
CD81,CR2	PI3K Signaling in B Lymphocytes
CR2	IL-8 Signaling NF-κB Activation by Viruses Complement System
GLP1R	Gαs Signaling GPCR-Mediated Integration of Enteroendocrine Signaling Exemplified by an L Cell G-Protein Coupled Receptor Signaling
AGTR2	cAMP-mediated signaling
IFITM3, IFITM1	Interferon Signaling
NME5	Salvage Pathways of Pyrimidine Ribonucleotides Pyrimidine Ribonucleotides <i>De Novo</i> Biosynthesis Pyrimidine Ribonucleotides Interconversion Pyrimidine Deoxyribonucleotides <i>De Novo</i> Biosynthesis I
SPTA1	Sertoli Cell-Sertoli Cell Junction Signaling
TLR7	Role of Macrophages Fibroblasts and Endothelial Cells in Rheumatoid Arthritis Colorectal Cancer Metastasis Signaling Systemic Lupus Erythematosus Signaling NF-κB Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses phagosome formation Communication between Innate and Adaptive Immune Cells Crosstalk between Dendritic Cells and Natural Killer Cells Altered T Cell and B Cell Signaling in Rheumatoid Arthritis TREM1 Signaling Toll-like Receptor Signaling
UIMC1	Role of BRCA1 in DNA Damage Response

Table 2. Gene Ontology Biological Process terms associated with interactors. Novel interactors are shown in bold.

Interactor	Gene Ontology Terms
AGTR2	Angiotensin receptor activity Angiotensin type ii receptor activity Receptor antagonist activity Receptor inhibitor activity Glucagon receptor activity Peptide receptor activity, G-protein coupled Peptide receptor activity Receptor signaling protein activity
ARPC1B	Structural constituent of cytoskeleton
CR2	Complement receptor activity Complement binding
DEAF1	Neural Tube Closure Regulation Of Transcription From RNA Polymerase II Promoter Transcription From RNA Polymerase II Promoter Germ Cell Development Visual Learning Anatomical Structure Morphogenesis Regulation Of Mammary Gland Epithelial Cell Proliferation Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated Embryonic Skeletal System Development
NME5	Nucleoside diphosphate kinase activity
SPTA1	Structural constituent of cytoskeleton
TLR7	siRNA binding
UIMC1	K63-linked polyubiquitin binding Polyubiquitin binding
VKORC1	Oxidoreductase activity, acting on the CH-OH group of donors, disulfide as acceptor Vitamin-K-epoxide reductase (warfarin-sensitive) activity Vitamin-K-epoxide reductase (warfarin-insensitive) activity

Table 3. Interacting genes that are differentially-expressed under Zika virus infection, along with fold-change and significant p-values.

Interactor	Log-2 Fold Change	p-value
FNDC3B	0.92	0.00005
NME5	-1.55	0.00005
RASSF7	-0.46	0.00215
UIMC1	0.73	0.00005
CD81	-0.28	0.00325

Discussion

Our goal here is to release the novel PPIs of IFITMs that we could predict computationally, recognizing their importance in mediating immune response in ZIKV infection. These predictions were obtained by using an experimentally and computationally validated algorithm HiPPIP, and are estimated to be highly accurate. Novel PPIs of IFITM1 and IFITM3 shed light on possible mechanisms of host invasion adopted by Zika virus including suppression of the immune system and cognitive and birth defects following infection. Based on the predicted protein-protein interactions, and the functions of the interacting proteins, we formulated three hypotheses about mechanisms of Zika virus infection.

Cilia dysfunction in ependymal cells may be associated with microcephaly induced by Zika virus

IFITM1 and three of the novel interactors (NME5, UIMC1 and DYNLT3) were found in cilia interactome (i.e. interactome of proteins of the organelle cilia), and seemed to be associated with processes that led to hydrocephalus, a condition frequently associated with ciliopathies, in which cerebrospinal fluid accumulate in the brain ventricle giving rise to an enlarged head, viz. dysfunction of ciliated ependymal cells in the brain (unpublished results)⁵⁵. The fact that multiciliated ependyma is infected by a wide variety of viruses, possess motile cilia, micro villi and adherens junctions and also mediate cellular infiltration into the CNS indicate that it may be functioning as an immunological barrier^{56,57}. This may point at the possibility that the multiciliated ependymal functions as a barrier which is also susceptible to the mechanisms of host invasion adopted by Zika virus and that cilia dysfunction may be a potential mechanism. In a recent study, delay in cilia disassembly was identified to be the cause of premature differentiation of neural progenitor cells (NPCs) in the ventricular zone which led to microcephaly⁵⁸. In an earlier study, the same group linked premature differentiation of NPCs to infection by Zika virus and impaired brain cellularity and structural organization of the cortical plate that follows⁵⁹.

While it has been established that defects in adhesion of ependymal cells and formation of cilia lead to hydrocephaly, its shared mechanisms with microcephaly, within the context of Zika infection has not been studied extensively. Interestingly, it has been reported that radial glial cells (RGCs), that give rise to ependymal cells, and astrocytes are more susceptible to infection by Zika virus than neurons⁶⁰. Moreover, RGCs constitute a barrier between brain parenchyma- a site of Zika infection- and ventricles from the embryonic stage⁶¹. Fetal mice infected with Zika virus exhibit a reduction in the size of lateral ventricles⁶². It has also been suggested that genes implicated in microcephaly may also influence the development of hydrocephalus. For example, ASPM which has undergone rapid evolution over the course of recent evolution of hominids is implicated in the size of cerebral cortex and neurogenesis and is also associated with primary microcephaly⁶³. The identification of ASH domains in ASPM has indicated that it may also be implicated in cilia dysfunction and hydrocephalus⁶⁴. ASH domains are normally found in proteins that localize to cilia, such as Hydin and OCRL which are associated with microcephaly and Lowe oculocerebrorenal syndrome respectively^{65,66}. In this respect, it has also been observed that injection of pregnant mice with Zika virus, leads to infection of RGCs that are responsible for cortex development located in the dorsal ventricular zone of fetal mice⁶⁷.

The expression of IFITM1 in endothelial cells of various organs such as the bladder, brain and stomach is correlated with the maturation of blood vessels⁶⁸. It is induced during maturation stages of angiogenesis in vitro while in vivo it is stably expressed by microvascular endothelial cells which are quiescent⁶⁸. A role for IFITM1 in formation of stable contacts between cells during lumen formation in endothelial tissue was revealed by a study. On knockdown of IFITM1, intercellular vacuoles failed to fuse and form a multicellular lumen due to the mislocalization of OCLN (occludin), which normally interacts with IFITM1 and localizes to

tight junctions between endothelial cells⁶⁸. It was speculated that the mechanism allowing IFITM1 to regulate assembly of tight junctions may be related to endosomal trafficking since internalized OCLN is returned to the plasma membrane from recycling endosomes during remodeling of tight junctions in endothelial cells. IFITM1 has also been shown to function in the endosomal pathway to inhibit viral infection⁶⁹. Microcephaly may arise due to dysfunctional DNA repair systems that lead to increased apoptosis of neural progenitor cells having a low endurance for damage and under normal conditions, migrate to the cortical plate to form various structures in the brain⁷⁰. Depletion of RAB80 or UIMC1- a novel interactor of IFITM1- which occurs in a complex with p73 when overexpressed, impairs translocation of BRCA1 to DNA damage sites resulting in defective control of cell cycle and repair of double strand breaks^{71,72}. p73 has been implicated in the development and maintenance of ependymal cells and in animals deficient in p73, increased apoptosis and lack of differentiation of RGCs into ependymal cells accompanied by loss of motile cilia resulting in hydrocephalus and hippocampal dysgenesis were reported^{73,74}. NME5 is highly expressed in ependymal cells and moderate to marked hydrocephalus along with ciliary dysfunction has been observed in mice homozygous for NME5⁷⁵. It is known that patients with HSV-2 (Herpes simplex virus-2) infection are more susceptible to the teratogenic effects induced by Zika virus, since HSV-2 infection enhances the sensitivity of placental tissue which facilitates the entry of Zika virus into cells mediated by TAM receptors that recognize pathogen associated molecular patterns (PAMPs)^{76,77}. It has been shown that VP26, the capsid surface protein of HSV, interacts with DYNLT3 which is a component of the motor protein, cytoplasmic dynein 1, mediating retrograde movement of vesicles and organelles along microtubules within cells⁷⁸.

RASSF7 (another novel interactor of IFITM1), has been shown to directly interact with DISC1 whose role in formation of astrocytes, which express primary cilia, in the embryonic brain via modulation of RAS/MEK/ERK signaling has been revealed in a study^{79,80}. RASSF7 is a centrosomal protein that regulates microtubule dynamics, the knockdown of which in *Xenopus* has been reported to cause nuclear breakdown, apoptosis and loss of tissue architecture in the neural tube⁸¹. One of the novel interactors predicted for IFITM3 is DEAF1, mutations in which has been linked to white matter disease, microcephaly and syndromic intellectual disability using whole exome sequencing⁸². Exencephaly has been observed in mice homozygous for DEAF1 which is involved in the development of the neural tube⁸³. TSSC4 is associated with Beckwith Wiedemann syndrome which is incidentally also characterized by microcephaly in addition to other physical manifestations and interacts with CEP76, a candidate gene associated with autosomal recessive congenital microcephaly and found in ciliated cells⁸⁴⁻⁸⁶. The novel interactor PHLDA2 is also associated with Beckwith Wiedemann syndrome⁸⁷.

Inhibitory action of IFITM1 may be mediated by effector functions of natural killer cells which may also be targeted for immunosuppression

The novel interactions of TLR7 and CD81 with IFITM1 opens up the possibility that the inhibitory action of IFITM1 on Zika virus may be mediated by effector functions of natural killer

(NK) cells. At the same time, it has been shown that Zika viruses evade anti-viral responses by inhibiting interferon-mediated signaling⁸⁸. So, the novel interactions of TLR7 and CD81 with IFITM1 may also serve as potential targets of Zika virus by which it suppresses immune responses of the host.

NK cells when activated combat infection by Zika virus⁸⁹. TLR7 (a novel interactor predicted for IFITM1) recognizes viral RNA in endosomes and mounts defense mechanisms against flaviviruses including JEV (Japanese encephalitis virus) by activating NK cells to stimulate secretion of pro-inflammatory cytokines, increase microglial activation and infiltration of peripheral immune cells in the brain^{90,91}. Mice with TLR7 knocked out have been shown to be more susceptible to infection by JEV⁹². Another novel interactor of IFITM1- CD81 inhibits functions of NK cells when cross linked with HCV (Hepatitis C virus) and associates with GRP56 which negatively regulates effector responses of NK-92 cells dependent on IL-2 signaling including secretion of pro-inflammatory cytokines and cytolytic proteins⁹³. Also, malformations associated with microcephaly syndrome have been reported in patients with null GPR56⁹⁴.

Proteins that influence cytoskeletal events may be targeted by Zika virus to facilitate host invasion

Infection by Zika virus has been known to cause drastic reorganization of cytoskeletal structures surrounding replication factories in the cell, which are regions of the endoplasmic reticulum re-modeled following viral infection to allow viral replication⁹⁵. The novel interactions of FNDC3B with IFITM3 and SPTA1, ARPC1B and AGTR2 with IFITM1 may shed light on mechanisms of host invasion underlying cytoskeletal rearrangements that follow Zika virus infection.

FNDC3B- a novel interactor of IFITM3 promotes cell migration by cooperating with ANXA2⁹⁶. FNDC3B has been found to be upregulated in samples of hepatocellular carcinoma infected with HBV (Hepatitis B virus) or HCV and overexpressed in normal liver tissue infected with viral hepatitis⁹⁶. It has also been reported that the expression of FNDC3B increases on induction of GDF-15 which is known to regulate expression of genes that orchestrate changes in cytoskeleton and adhesion junctions⁹⁷. In this respect, it is interesting to note that IFITM3 has been suggested to inhibit early stages of Zika virus infection by directly altering the properties of cell and/or viral membranes and blocking formation of fusion pores⁹⁸. SPTA1 is associated with spinocerebellar ataxia which also has microcephaly as one of its physical manifestations⁹⁹. Spectrins form complexes with

intracellular networks by interacting with actin, ankyrin and adducin⁹⁹. Deletion of adducin gives rise to lethal hydrocephalus in mice¹⁰⁰. Spectrins influence cell adhesion and spreading and are also found in the cortical cytoplasm of ependymal cells⁹⁹. It has been reported that OSGEP and TP53RK, both of which are implicated in nephrotic syndrome with primary microcephaly, interact with components of the ARP2/3 complex including ARPC1B involved in actin remodeling at lamellipodia^{101,102}. Lesions in white matter found in elderly people have been associated with polymorphisms in AGTR2, a novel interactor of IFITM1 and an antagonist of AGTR1, which influences angiogenesis induced by VEGF¹⁰³. Cytoskeletal events guided by VEGF signaling are known to orchestrate formation of vascular lumen, which might contribute to the development of microcephaly¹⁰⁴.

Other resources

See <http://severus.dbmi.pitt.edu/schizo-pi> or <http://severus.dbmi.pitt.edu/wiki-pi> for annotations compiled from various databases for each of the individual proteins.

Data availability

All pertaining data are provided in the manuscript.

Author contributions

JCM was undergraduate student at University of Puerto Rico, and contributed to this work through internship at University of Pittsburgh.

Competing interests

No competing interests were disclosed.

Grant information

MKG's work is funded by Biobehavioral Research Awards for Innovative New Scientists (BRAINS) grant (R01MH094564) from National Institute of Mental Health of National Institutes of Health of USA.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

MKG and KBK thank Prof. N. Balakrishnan (Indian Institute of Science) for discussions and support. MKG thanks her students Mara Staines, Varsha Embar and Srilakshmi Chaparala for assisting in this work.

References

- Dick GW, Kitchen SF, Haddock AJ: **Zika virus. I. Isolations and serological specificity.** *Trans R Soc Trop Med Hyg.* 1952; 46(5): 509–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Valadão AL, Aguiar RS, de Arruda LB: **Interplay between Inflammation and Cellular Stress Triggered by Flaviviridae Viruses.** *Front Microbiol.* 2016; 7: 1233.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Smit JM, Moesker B, Rodenhuis-Zybert I, et al.: **Flavivirus cell entry and membrane fusion.** *Viruses.* 2011; 3(2): 160–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Higgs S: **Zika Virus: Emergence and Emergency.** *Vector Borne Zoonotic Dis.* 2016; 16(2): 75–6.
[PubMed Abstract](#) | [Publisher Full Text](#)

5. Lazear HM, Diamond MS: **Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere.** *J Virol.* 2016; **90**(10): 4864–4875. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Petersen E, Wilson ME, Touch S, *et al.*: **Rapid Spread of Zika Virus in The Americas—Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games.** *Int J Infect Dis.* 2016; **44**: 11–5. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Savidis G, Perreira JM, Portmann JM, *et al.*: **The IFITMs Inhibit Zika Virus Replication.** *Cell Rep.* 2016; **15**(11): 2323–30. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Araujo LM, Ferreira ML, Nascimento OJ: **Guillain-Barré syndrome associated with the Zika virus outbreak in Brazil.** *Arq Neuropsiquiatr.* 2016; **74**(3): 253–5. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Cao-Lormeau VM, Blake A, Mons S, *et al.*: **Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.** *Lancet.* 2016; **387**(10027): 1531–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Broutet N, Krauer F, Riesen M, *et al.*: **Zika Virus as a Cause of Neurologic Disorders.** *N Engl J Med.* 2016; **374**(16): 1506–1509. [PubMed Abstract](#) | [Publisher Full Text](#)
11. de Paula Freitas B, de Oliveira Dias JR, Prazeres J, *et al.*: **Ocular Findings in Infants With Microcephaly Associated With Presumed Zika Virus Congenital Infection in Salvador, Brazil.** *JAMA Ophthalmol.* 2016; **134**(5): 529–535. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Hazin AN, Poretti A, Di Cavalcanti Souza Cruz D, *et al.*: **Computed Tomographic Findings in Microcephaly Associated with Zika Virus.** *N Engl J Med.* 2016; **374**(22): 2193–5. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Malakar J, Korva M, Tul N, *et al.*: **Zika Virus Associated with Microcephaly.** *N Engl J Med.* 2016; **374**(10): 951–8. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Moron AF, Cavalheiro S, Milani H, *et al.*: **Microcephaly associated with maternal Zika virus infection.** *BJOG.* 2016; **123**(8): 1265–1269. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Carod-Artal FJ: **Epidemiology and neurological complications of infection by the Zika virus: a new emerging neurotropic virus.** *Rev Neurol.* 2016; **62**(7): 317–328. [PubMed Abstract](#)
16. Tang H, Hammack C, Ogden SC, *et al.*: **Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth.** *Cell Stem Cell.* 2016; **18**(5): 587–590. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Waddell LA, Greig JD: **Scoping Review of the Zika Virus Literature.** *PLoS One.* 2016; **11**(5): e0156376. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Krauer F, Riesen M, Reveiz L, *et al.*: **Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain-Barré Syndrome: Systematic Review.** *PLoS Med.* 2017; **14**(1): e1002203. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Rasmussen SA, Jamieson DJ, Honein MA, *et al.*: **Zika Virus and Birth Defects—Reviewing the Evidence for Causality.** *N Engl J Med.* 2016; **374**(20): 1981–7. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Sun X, Zeng H, Kumar A, *et al.*: **Constitutively Expressed IFITM3 Protein in Human Endothelial Cells Poses an Early Infection Block to Human Influenza Viruses.** *J Virol.* 2016; **90**(24): 11157–67. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. O'Connor MJ, Lind C, Tang X, *et al.*: **Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood.** *J Heart Lung Transplant.* 2013; **32**(4): 390–7. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Gorman MJ, Poddar S, Farzan M, *et al.*: **The Interferon-Stimulated Gene *Ifttm3* Restricts West Nile Virus Infection and Pathogenesis.** *J Virol.* 2016; **90**(18): 8212–25. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Brass AL, Huang IC, Benita Y, *et al.*: **The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.** *Cell.* 2009; **139**(7): 1243–54. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Huang IC, Bailey CC, Weyer JL, *et al.*: **Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.** *PLoS Pathog.* 2011; **7**(1): e1001258. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Smith S, Weston S, Kellam P, *et al.*: **IFITM proteins—cellular inhibitors of viral entry.** *Curr Opin Virol.* 2014; **4**: 71–7. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Poddar S, Hyde JL, Gorman MJ, *et al.*: **The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses.** *J Virol.* 2016; **90**(19): 8780–94. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Altan-Bonnet N: **Lipid Tales of Viral Replication and Transmission.** *Trends Cell Biol.* 2017; **27**(3): 201–213. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. den Boon JA, Ahlquist P: **Organelle-like membrane compartmentalization of positive-strand RNA virus replication factories.** *Annu Rev Microbiol.* 2010; **64**: 241–56. [PubMed Abstract](#) | [Publisher Full Text](#)
29. Miller S, Krijnse-Locker J: **Modification of intracellular membrane structures for virus replication.** *Nat Rev Microbiol.* 2008; **6**(5): 363–74. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Quicke KM, Suthar MS: **The innate immune playbook for restricting West Nile virus infection.** *Viruses.* 2013; **5**(11): 2643–58. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Pierson TC, Graham BS: **Zika Virus: Immunity and Vaccine Development.** *Cell.* 2016; **167**(3): 625–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Bayer A, Lennemann NJ, Ouyang Y, *et al.*: **Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection.** *Cell Host Microbe.* 2016; **19**(5): 705–12. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Hamel R, Dejarnac O, Wichit S, *et al.*: **Biology of Zika Virus Infection in Human Skin Cells.** *J Virol.* 2015; **89**(17): 8880–96. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Cohen FS, Melikyan GB: **The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement.** *J Membr Biol.* 2004; **199**(1): 1–14. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Amini-Bavil-Olyaei S, Choi YJ, Lee JH, *et al.*: **The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry.** *Cell Host Microbe.* 2013; **13**(4): 452–64. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Lazear HM, Govero J, Smith AM, *et al.*: **A Mouse Model of Zika Virus Pathogenesis.** *Cell Host Microbe.* 2016; **19**(5): 720–30. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Bailey CC, Huang IC, Kam C, *et al.*: **Ifttm3 limits the severity of acute influenza in mice.** *PLoS Pathog.* 2012; **8**(9): e1002909. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Bailey CC, Zhong G, Huang IC, *et al.*: **IFITM-Family Proteins: The Cell's First Line of Antiviral Defense.** *Annu Rev Virol.* 2014; **1**: 261–83. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Ganapathiraju MK, Tahiri M, Handen A, *et al.*: **Schizophrenia interactome with 504 novel protein-protein interactions.** *NPJ Schizophr.* 2016; **2**: 16012. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Zhu J, Zhang Y, Ghosh A, *et al.*: **Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor.** *Immunity.* 2014; **40**(6): 936–48. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Ganapathiraju MK, Tahiri M, Handen A, *et al.*: **Schizophrenia interactome with 504 novel protein-protein interactions.** *NPJ Schizophr.* 2016; **2**: 16012. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Li Y, Klena NT, Gabriel GC, *et al.*: **Global genetic analysis in mice unveils central role for cilia in congenital heart disease.** *Nature.* 2015; **521**(7553): 520–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Malavia TA, Chaparala S, Wood J, *et al.*: **Generating testable hypotheses for schizophrenia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data.** *NPJ Schizophr.* 2017; **3**: 11, in Press. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Peri S, Navarro JD, Kristiansen TZ, *et al.*: **Human protein reference database as a discovery resource for proteomics.** *Nucleic Acids Res.* 2004; **32**(Database issue): D497–501. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Stark C, Breitkreutz BJ, Reguly T, *et al.*: **BioGRID: a general repository for interaction datasets.** *Nucleic Acids Res.* 2006; **34**(Database issue): D535–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Qi Y, Dhiman HK, Bhola N, *et al.*: **Systematic prediction of human membrane receptor interactions.** *Proteomics.* 2009; **9**(23): 5243–55. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Shannon P, Markiel A, Ozier O, *et al.*: **Cytoscape: a software environment for integrated models of biomolecular interaction networks.** *Genome Res.* 2003; **13**(11): 2498–504. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Maere S, Heymans K, Kuiper M: **BINGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks.** *Bioinformatics.* 2005; **21**(16): 3448–9. [PubMed Abstract](#) | [Publisher Full Text](#)
49. Orii N, Ganapathiraju MK: **Wiki-pi: a web-server of annotated human protein-protein interactions to aid in discovery of protein function.** *PLoS One.* 2012; **7**(11): e49029. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Jensik PJ, Vargas JD, Reardon SN, *et al.*: **DEAF1 binds unmethylated and variably spaced CpG dinucleotide motifs.** *PLoS One.* 2014; **9**(12): e115908. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Vulto-van Silfhout AT, Rajamanickam S, Jensik PJ, *et al.*: **Mutations affecting the SAND domain of DEAF1 cause intellectual disability with severe speech impairment and behavioral problems.** *Am J Hum Genet.* 2014; **94**(5): 649–61. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Ordureau A, Enesa K, Nanda S, *et al.*: **DEAF1 is a Pellino1-interacting protein**

- required for interferon production by Sendai virus and double-stranded RNA. *J Biol Chem*. 2013; **288**(34): 24569–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Boguslawska DM, Machnicka B, Hryniewicz-Jankowska A, et al.: Spectrin and phospholipids - the current picture of their fascinating interplay. *Cell Mol Biol Lett*. 2014; **19**(1): 158–79.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Liu B, Liu Q, Yang L, et al.: Innate immune memory and homeostasis may be conferred through crosstalk between the TLR3 and TLR7 pathways. *Sci Signal*. 2016; **9**(436): ra70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Waters AM, Beales PL: Ciliopathies: an expanding disease spectrum. *Pediatr Nephrol*. 2011; **26**(7): 1039–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Del Bigio MR: Ependymal cells: biology and pathology. *Acta neuropathologica*. 2010; **119**(1): 55–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Jiménez AJ, Domínguez-Pinos MD, Guerra MM, et al.: Structure and function of the ependymal barrier and diseases associated with ependyma disruption. *Tissue Barriers*. 2014; **2**(1): e28426.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Gabriel E, Gopalakrishnan J: Generation of iPSC-derived Human Brain Organoids to Model Early Neurodevelopmental Disorders. *J Vis Exp*. 2017; (122): e55372.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Gabriel E, Ramani A, Karow U, et al.: Recent Zika Virus Isolates Induce Premature Differentiation of Neural Progenitors in Human Brain Organoids. *Cell stem cell*. 2017; **20**(3): 397–406.e5.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Retallack H, Di Lullo E, Arias C, et al.: Zika virus cell tropism in the developing human brain and inhibition by azithromycin. *Proc Natl Acad Sci U S A*. 2016; **113**(50): 14408–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Solomon IH, Milner DA, Folkher RD: Neuropathology of Zika Virus Infection. *J Neuroinfect Dis*. 2016; **7**(2): pii: 220.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Brault JB, Khou C, Basset J, et al.: Comparative Analysis Between Flaviviruses Reveals Specific Neural Stem Cell Tropism for Zika Virus in the Mouse Developing Neocortex. *EBioMedicine*. 2016; **10**: 71–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Kouprina N, Pavlicek A, Mochida GH, et al.: Accelerated evolution of the *ASPM* gene controlling brain size begins prior to human brain expansion. *PLoS Biol*. 2004; **2**(5): E126.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Ponting CP: A novel domain suggests a ciliary function for *ASPM*, a brain size determining gene. *Bioinformatics*. 2006; **22**(9): 1031–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Swan LE, Tomasini L, Pirruccello M, et al.: Two closely related endocytic proteins that share a common OCLR-binding motif with APPL1. *Proc Natl Acad Sci U S A*. 2010; **107**(8): 3511–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Dawe HR, Shaw MK, Farr H, et al.: The hydrocephalus inducing gene product, Hydin, positions axonemal central pair microtubules. *BMC Biol*. 2007; **5**(1): 33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Wang JN, Ling F: Zika Virus Infection and Microcephaly: Evidence for a Causal Link. *Int J Environ Res Public Health*. 2016; **13**(10): pii: E1031.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Popson SA, Ziegler ME, Chen X, et al.: Interferon-induced transmembrane protein 1 regulates endothelial lumen formation during angiogenesis. *Arterioscler Thromb Vasc Biol*. 2014; **34**(5): 1011–9, ATVBAHA. 114.303352.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Li K, Jia R, Li M, et al.: A sorting signal suppresses IFITM1 restriction of viral entry. *J Biol Chem*. 2015; **290**(7): 4248–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. O'Driscoll M, Jeggo PA: The role of the DNA damage response pathways in brain development and microcephaly: insight from human disorders. *DNA Repair (Amst)*. 2008; **7**(7): 1039–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Yan J, Jetten AM: RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. *Cancer Lett*. 2008; **271**(2): 179–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. Marshall CB: The Essential Role of p73 in Multiciliated Cell Development. 2016. [Reference Source](#)
73. Gonzalez-Cano L, Fuertes-Alvarez S, Robledinos-Anton N, et al.: p73 is required for ependymal cell maturation and neurogenic SVZ cytoarchitecture. *Dev Neurobiol*. 2016; **76**(7): 730–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Marshall CB, Mays DJ, Beeler JS, et al.: p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. *Cell Rep*. 2016; **14**(10): 2289–300.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Vogel P, Read RW, Hansen GM, et al.: Congenital hydrocephalus in genetically engineered mice. *Vet Pathol*. 2012; **49**(1): 166–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Aldo P, You Y, Szigeti K, et al.: HSV-2 enhances ZIKV infection of the placenta and induces apoptosis in first-trimester trophoblast cells. *Am J Reprod Immunol*. 2016; **76**(5): 348–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Newton K, Dixit VM: Signaling in innate immunity and inflammation. *Cold Spring Harb Perspect Biol*. 2012; **4**(3): pii: a006049.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Döhner K, Radtke K, Schmidt S, et al.: Eclipse phase of herpes simplex virus type 1 infection: Efficient dynein-mediated capsid transport without the small capsid protein VP26. *J Virol*. 2006; **80**(16): 8211–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Wang S, Liang Q, Qiao H, et al.: DISC1 regulates astrogenesis in the embryonic brain via modulation of RAS/MEK/ERK signaling through RASSF7. *Development*. 2016; **143**(15): 2732–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Yoshimura K, Kawate T, Takeda S: Signaling through the primary cilium affects glial cell survival under a stressed environment. *Glia*. 2011; **59**(2): 333–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Sherwood V, Manboth R, Sheppard C, et al.: RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. *Mol Biol Cell*. 2008; **19**(4): 1772–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Faqeih EA, Al-Owain M, Colak D, et al.: Novel homozygous *DEAF1* variant suspected in causing white matter disease, intellectual disability, and microcephaly. *Am J Med Genet A*. 2014; **164A**(6): 1565–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Hahm K, Sum EY, Fujiwara Y, et al.: Defective neural tube closure and anteroposterior patterning in mice lacking the LIM protein LMO4 or its interacting partner Deaf-1. *Mol Cell Biol*. 2004; **24**(5): 2074–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Cerrato F, Sparago A, Di Matteo I, et al.: The two-domain hypothesis in Beckwith-Wiedemann syndrome: autonomous imprinting of the telomeric domain of the distal chromosome 7 cluster. *Hum Mol Genet*. 2005; **14**(4): 503–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Hassan MJ, Chishti MS, Jamal SM, et al.: A syndromic form of autosomal recessive congenital microcephaly (Jawad syndrome) maps to chromosome 18p11.22-q11.2. *Hum Genet*. 2008; **123**(1): 77–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Tsang WY, Spektor A, Vijayakumar S, et al.: Cep76, a centrosomal protein that specifically restrains centriole reduplication. *Dev Cell*. 2009; **16**(5): 649–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Oh-McGinnis R, Bogutz AB, Lee KY, et al.: Rescue of placental phenotype in a mechanistic model of Beckwith-Wiedemann syndrome. *BMC Dev Biol*. 2010; **10**(1): 50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Wu Y, Liu Q, Zhou J, et al.: Zika virus evades interferon-mediated antiviral response through the co-operation of multiple nonstructural proteins *in vitro*. *Cell Discov*. 2017; **3**: 17006.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Glasner A, Oiknine-Djian E, Weisblum Y, et al.: Zika virus escapes NK cell detection by upregulating MHC class I molecules. *J Virol*. 2017; pii: JVI.00785-17.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Xagorari A, Chlichlia K: Toll-like receptors and viruses: induction of innate antiviral immune responses. *Open Microbiol J*. 2008; **2**: 49–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Nazmi A, Mukherjee S, Kundu K, et al.: TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection. *Neurobiol Dis*. 2014; **69**: 235–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Awais M, Wang K, Lin X, et al.: TLR7 Deficiency leads to TLR8 compensative regulation of immune response against JeV in Mice. *Front Immunol*. 2017; **8**: 160.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Chang GW, Hsiao CC, Peng YM, et al.: The adhesion G protein-coupled receptor GPR56/ADGRG1 is an inhibitory receptor on human NK cells. *Cell Rep*. 2016; **15**(8): 1757–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Squier W, Jansen A: Polymicrogyria: pathology, fetal origins and mechanisms. *Acta Neuropathol Commun*. 2014; **2**(1): 80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Cortese M, Goellner S, Acosta EG, et al.: Ultrastructural Characterization of Zika Virus Replication Factories. *Cell Rep*. 2017; **18**(9): 2113–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. Lin CH, Lin YW, Chen YC, et al.: *FNDC3B* promotes cell migration and tumor metastasis in hepatocellular carcinoma. *Oncotarget*. 2016; **7**(31): 49498–49508.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Muralidharan AR, Maddala R, Skiba NP, et al.: Growth Differentiation Factor-15-Induced Contractile Activity and Extracellular Matrix Production in

- Human Trabecular Meshwork Cells.** *Invest Ophthalmol Vis Sci.* 2016; **57**(15): 6482–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Savidis G, Perreira JM, Portmann JM, *et al.*: **The IFITMs Inhibit Zika Virus Replication.** *Cell Rep.* 2016; **15**(11): 2323–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Zhang R, Zhang C, Zhao Q, *et al.*: **Spectrin: structure, function and disease.** *Sci China Life Sci.* 2013; **56**(12): 1076–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Leite SC, Sampaio P, Sousa VF, *et al.*: **The actin-binding protein α -Adducin is required for maintaining axon diameter.** *Cell Rep.* 2016; **15**(3): 490–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Braun DA, Rao J, Mollet G, *et al.*: **Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly.** *Nat Genet.* 2017; **49**(10): 1529–1538.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Goley AD, Welch MD: **The ARP2/3 complex: an actin nucleator comes of age.** *Nat Rev Mol Cell Biol.* 2006; **7**(10): 713–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Taylor WD, Steffens DC, Ashley-Koch A, *et al.*: **Angiotensin receptor gene polymorphisms and 2-year change in hypertensive lesion volume in men.** *Mol Psychiatry.* 2010; **15**(8): 816–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Ma H, Tochigi A, Shearer TR, *et al.*: **Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells.** *J Ocul Pharmacol Ther.* 2009; **25**(5): 409–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Referee Status:



Version 2

Referee Report 02 January 2018

doi:10.5256/f1000research.13765.r28220



Nicholas Eyre

School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia

The changes included in this revised manuscript somewhat improve the description of the HiPPiP model and add some useful (albeit highly speculative) discussion of the potential mechanisms of IFITM antiviral activities against ZIKV. However, I am still not entirely convinced of the validity of the HiPPiP model and some of the the statements supporting this model appear to be exaggerated (e.g. *"Thus, the novel PPIs predicted by HiPPiP are highly dependable to lead to successful experiments"* - I am not sure what this means, and *"Furthermore, predicted PPIs with scores ranging from 0.41 to 0.65 were experimentally validated and found to be true interacting pairs"* - I am not convinced about the experimental validation detailed in this prior publication as the presented immunoprecipitation data does not include appropriate negative controls, molecular weight markers, details about antibody sources or specificity etc.). Future studies of this nature would be greatly strengthened by experimental validation of computationally predicted protein-protein interactions and exploration of the importance of the candidate host factors for the ZIKV replication cycle (e.g. via knockdown / knockout and/or pharmacological targeting of the candidate host factor and examination of effects on the ZIKV replication cycle).

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Referee Report 20 December 2017

doi:10.5256/f1000research.13765.r28662



Rama Rao Damerla 

Memorial Sloan Kettering Cancer Center, New York, NY, USA

The manuscript in review uses a previously tested model of protein-protein interaction (PPI) called High-confidence Protein-Protein Interaction Prediction (HiPPiP) to predict novel PPIs of two small membrane-associated interferon-inducible transmembrane proteins IFITM1 and IFITM3. The authors cite previously reported data on the role of IFITM1 and IFITM3 in inhibiting Zika virus (ZIKV) and make a valid argument that the novel PPIs of IFITM1 and IFITM3 from the HiPPiP model could possibly predict mechanisms of host invasion and immune suppression by Zika virus (ZIKV) and members of its family

Flaviviridae. They also analyze functional and pathway associations of the interacting proteins and discuss possible roles of these proteins as targets for ZIKV infection. The title, abstract and article are clearly presented and make an engaging read. Although the authors present an extensive discussion on novel interactors, the article ends arbitrarily. A conclusion paragraph summarizing the results and presenting new ideas for future research would be apt.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: Dr. Ganapathyraju and I are co-authors on one publication titled "Global genetic analysis in mice unveils central role for cilia in congenital heart disease" published in Nature (May 2015). I was part of this publication for mapping mutations in mutant mice with congenital heart disease using next generation sequencing. Dr. Ganapathyraju had constructed an interactome with the genes recovered from the forward genetic screen.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 22 November 2017

doi:10.5256/f1000research.13765.r28221



Judith Klein-Seetharaman

Division of Metabolic and Vascular Health, University of Warwick, Warwick, UK

Looks good

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Referee Report 12 January 2017

doi:10.5256/f1000research.10083.r17282

**Sandeep Chakraborty**

Plant Sciences Department, University of California, Davis, CA, USA

This manuscript presents a use model of the a protein-protein interaction method developed by the author along with other collaborators, focused on a very important pathogen (Zika) in the present circumstances. It is lucidly written and well presented.

The biggest shortcoming of this manuscript is the failure to cite several previous work related to the interferon-inducible transmembrane protein 3 ("The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry" - Amini-Bavil-Olyaei, et. al, 2013, "The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry", Amini-Bavil-Olyaei, et. al, 2013 to name a couple).

Furthermore, the current manuscript and its stated methodology does not find two proteins (VAPA and OSBP) that have been shown to have interactions with IFITM3. This would have been a clincher. It would also be proper to mention other work related to IFITM mechanism ("IFITM Proteins Restrict Viral Membrane Hemifusion": Li et. al, 2013) - and focus on the viral membrane hemifusion mentioned there.

Minor comments:

1. "functional studies initiated solely" - capitalize functional.
2. Widespread use of "we" with only a single author.
3. "Computationally discovered PPIs have been shown to be highly accurate by computational evaluations and experimental validations of a few PPIs'." - overstated and speculative.
4. It is also speculative to correlate the expression changes of predicted interactors to these IFITMs, since there can be multiple other reasons for such expression changes ("whether any of the interacting genes were differentially expressed in that study and found five genes that were differentially expressed").

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Referee Report 08 December 2016

doi:10.5256/f1000research.10083.r17909



Nicholas Eyre

School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia

This manuscript reports a number of novel protein interactions of IFITM1 and IFITM3 proteins, as determined using a 'High-confidence Protein-Protein Interaction Prediction (HiPPIP)' computational prediction model of protein-protein interactions. Analysis of functional and pathway associations of the putative interacting proteins is also reported, as they may relate to IFITM-mediated restriction of Zika virus infection. The manuscript is generally well-written and the title is appropriate. However, there are several ways in which the study and manuscript could be improved:

1. The report is largely based upon the predictions generated by the HiPPIP model. As this model is not well-described here and has not been extensively validated experimentally in the literature, it would be helpful if the criteria/rules employed by the model were described (Are predictions based purely on structural features? Does the model take into account protein localization, regulation, tissue distribution, known interactions etc.?). In the Methods section it is simply stated that 'Computationally discovered PPIs have been shown to be highly accurate by computational evaluations and experimental validations of a few PPIs'. This statement is not well-justified and may be misleading. In support of the HiPPIP model, the author refers to the successful prediction of OASL interaction with RIG-I ('Functional studies initiated solely by this predicted PPI showed...'). However in the cited publication (on which Dr. Ganapathiraju is an author)¹ the HiPPIP model (and associated publications) was not referred to. The HiPPIP model should be more clearly described here, including some analysis/discussion of its success rate in predicting protein-protein interactions that have been experimentally validated.
2. As this report focuses on IFITM1 and IFITM3 antiviral functions and predicted interactions, it would be useful if the features and properties of these proteins were at least briefly described (domains, membrane topology, post-translational modifications, sub-cellular localization, tissue distribution and regulation). This would help to interpret the significance of the predicted interactions.
3. In the Results and Discussion some of the roles/properties of the predicted interacting partners are listed. It would be helpful if references were provided for these functions/properties (even if only to reviews). Furthermore, it would be helpful if these properties were discussed in the context of Zika virus and/or IFITM biology (e.g. commonalities in tissue/sub-cellular distribution and/or regulation and features of these proteins [e.g. domains] that may support their predicted interactions).
4. The manuscript should be carefully edited to clarify interactions that are purely predicted and not supported by experimental evidence (e.g. statements like 'TSSC4 interacts with IFITM1 and IFITM3' are misleading).
5. A conclusion/summary paragraph that briefly summarizes the major findings and their significance and potential future directions may be appropriate.

References

1. Zhu J, Zhang Y, Ghosh A, Cuevas RA, Forero A, Dhar J, Ibsen MS, Schmid-Burgk JL, Schmidt T, Ganapathiraju MK, Fujita T, Hartmann R, Barik S, Hornung V, Coyne CB, Sarkar SN: Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. *Immunity*. 2014; **40** (6): 936-48 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Referee Report 08 August 2016

doi:[10.5256/f1000research.10083.r15557](https://doi.org/10.5256/f1000research.10083.r15557)



Judith Klein-Seetharaman

Division of Metabolic and Vascular Health, University of Warwick, Warwick, UK

The title, abstract and article overall are well written and clear. The design, methods and analysis are mostly well described, although some detail could be added. In particular, given that the IFITM interactome contains a large number of previously unknown PPI's, it would be useful to give a little more detail on the methodology on how these predictions were obtained, rather than just stating that HiPPIP was used. In particular, it would be useful to understand what cut-off was used and a brief mentioning of the prediction methodology in general. An estimate of false positive and false negative errors for the prediction in Figure 1 would be particularly helpful.

In the analysis, the legend for Figure 2 needs expansion. It is not clear what the edges signify and in particular what is the meaning of directionality in the arrows.

I object to the wording used on page 2 "which was validated to be a true PPI", as any PPI evidence is debatable. I would reword to "which was experimentally validated".

I also object to the wording used on page 2 "Computationally discovered PPIs have been shown to be highly accurate". Such a blanket statement is clearly not true, as there are many predictions out there that are highly inaccurate. A more specific example needs to be provided here.

A minor suggestion is to replace "HiPPIP model" with "the HiPPIP model".

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research